FX Implications of the Trump VictoryThe FX market reaction to the Trump victory was just as most had predicted – for a few hours. But by the end of Wednesday the USD weakness that had been seen initially against the majors had evaporated and the USD finished the day higher across the board. It does seem that market predictions that Trump would undermine confidence in the USD and the US economy have been off the mark. Not only is...

Read more

Wednesday's Activity: Trepp’s Takeaways from the Presidential Election Results Excerpt on CMBS We see the Donald Trump victory last night as a possible net positive for the CMBS market on several fronts. First, there is certainly the possibility of a loosening of risk retention rules. This could potentially help boost CMBS issuance in the future, compared to what a CMBS world with risk retention might look like. In addition, the removal of the higher borrower costs that come with risk retention structures would make...

Read more

We’re heading into the holiday season – a time when people reflect on the past year and what they want to do better in the coming year. You also might hear some advice – welcome or otherwise – from family members as you gather together. If I can be so bold, the Vision Impact Institute (VII) has some advice to share, too – advice backed up by research. A recent report titled Making Eye Health a Population Health Imperative: Vision...

Read more

Employee stock ownership plans (ESOPs) provide companies, selling shareholders and employees numerous benefits. But before any of these stakeholders reap the numerous benefits of an ESOP, company management must commit significant time and resources to its formation and administration. From the onset, management must make the ESOP’s sustainability a priority, regardless of its ownership stake. This article discusses the importance of understanding the relationship between a company’s valuation and an ESOP’s sustainability. Specifically, companies should seriously consider employing certain...

Read more

Companies that develop software that functions as a medical device should be aware that the Food and Drug Administration (FDA) has issued draft guidance that, once finalized, will classify the endless variety of Software as a Medical Device (SaMD), and impose risk-based criteria for evaluating the safety and effectiveness of such software. The draft guidance, titled Software as a Medical Device (SaMD): Clinical Evaluation,” is an attempt to determine what type of clinical evaluation is appropriate for SaMD that...

Read more